imyeloma 2021

25 – 27 March 2021

VJHemOnc is proud to be an official media partner for iwMyeloma 2021, a high-level discussion forum for research leaders in the field of myeloma, in order to further our understanding of recent advances in myeloma and to encourage interactive discussion. The clinical management of myeloma is a key theme.

The iwMyeloma 2021 meeting Scientific Committee has targeted areas for discussion where new evidence, insights, therapies and approaches, have important clinical implications, including:

  • Defining the molecular basis of myeloma in the development of novel targets
  • Immune-based therapies
  • Measurable residual disease (MRD)

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Agenda (all times EST)

 

Thursday 25th March 2021

10.00am EST Introduction Day 1: Gareth Morgan & Kenneth Anderson

10.00-11.30 Session 1: Genetics of drug resistance and high-risk | Chairs: Gareth Morgan & Irene M. Ghobrial

  • Overview lecture: Drug-resistant and high-risk MM; Gareth Morgan
  • Genomics of SMM; Irene Ghobrial
  • Molecular definitions of high-risk; Leif Bergsagel
  • Melphalan signatures; Francesco Maura
  • Genomics of relapse; Niels Weinhold
  • Segmentation at presentation and relapse; Jonathon Keats
  • Genetic resistance to IMiDs; Sarah Gooding

 

11.30-12.15 Panel Discussion: Genetics of drug resistance and high-risk MM

Panel Chairs; Gareth Morgan, Irene M. Ghobrial, Ola Landgren, Jonathan Keats, Leif Bergsagel, Francesco Maura, Niels Weinhold, Saad Usmani.

Discussion points:

  • Standardizing the definition of high-risk
  • Criteria for molecular markers
  • Incorporating markers into trials
  • Standardized treatment HR
  • Drug resistance and its management

 

12.15-13:45 Session 2: Management of older, frail, and SMM patients  | Chairs: Maria-Victoria Mateos & Charlotte Pawlyn

  • Overview lecture: The clinical management of older patients; Sonja Zweegman    
  • Is there a role for genetic assessment in older patients; Eileen Boyle
  • Design of elderly trials and geriatric risk scores; Charlotte Pawlyn
  • Mass spec for monitoring MRD; Angela Dispenzieri
  • Interventions and update on current clinical trials for SMM; Maria-Victoria Mateos
  • iStopMM; Sigurdur Kristinsson
  • The of anti-CD38 for amyloid. Suzanne Lentzsch

 

13.45-14.30 Panel Discussion: The clinical management of older frail and SMM patients

Panel Chairs: Maria-Victoria Mateos, Charlotte Pawlyn, Suzanne Lentzsch, Sonja Zweegman, Eileen Boyle, Graham Jackson, Alessandra Larocca, Sigurdur Kristinsson, Angela Dispenzieri.

Discussion points:

  • Geriatric assessments and molecular assessments
  • What is the age cut-point for aggressive treatment?
  • Drug regimens for the elderly
  • Treating the frail

 

Friday 26th March 2021

10.00am EST Introduction Day 2: Gareth Morgan

10.30-11:30 Session 3: The clinical application of T-cell engagers in MM  | Chairs: Kenneth Anderson & Hermann Einsele

  • Overview lecture: The clinical application of T-cell engagers in MM; Ajai Chiari
  • Role of BCMA targeted ADC and bi-specifics; Sagar Lonial
  • Available targets and overview of CAR-T; Ruben Niezwisky
  • Deletions of BCMA as a marker of resistance; Leo Rasche
  • Can TCE overcome high-risk; Rafael Fonseca
  • Early and late complications of TCE including CAR-T and bispecifics; Samir Parekh
  • Combination immunotherapies; Ken Anderson

 

11.30-12.45 Panel Discussion: The clinical application of T-cell engagers in MM

Panel Chairs: Kenneth Anderson, Hermann Einsele, Sagar Lonial, Niels van den Donk, Ruben Niezwisky, Leo Rasche, Adam Cohen, Al Garfell, Ajai Chiari

Discussion points:

  • CAR-T vs bispecifics: is there adequate evidence to suggest which is most active?
  • Cost vs. efficacy
  • Will TCE replace or improve ASCT?

 

12.45-14:10 Session 4: Strategies for cure and the management of younger patients  | Chairs: Faith Davies & Pieter Sonneveld

  • Overview lecture: Cure and the management of younger patients. Jesus San Miguel
  • The role of ASCT, tandem ASCT and consolidation; Francesca Gay
  • Chemo-free approaches to cure: Ola Landgren
  • Current and future of management of HR: melphalan flufenamide in rMM: Pieter Sonneveld
  • Stamina trial update; Sergio Giralt
  • Role of consolidation; Philippe Moreau
  • Maintenance strategies: ixazomib; Faith Davies

 

14.10-14.55 Panel Discussion: Cure and the management of younger patients

Panel Chairs: Faith Davies, Pieter Sonneveld, Jesus San Miguel, Francesca Gay, Ola Landgren, Rafael Fonseca, Sergio Giralt, Philippe Moreau

 

Saturday 27th March 2021

10.00am EST Introduction Day 3: Keith Stewart

10.10-11:40 Session 5: The development and integration of novel targets  | Chairs: Jonathan Kaufman & Keith Stewart

  • Overview lecture: The development and integration of novel targets; Keith Stewart 
  • Mass spec for monitoring MRD; Angela Dispenzieri
  • MCL1, BCL2 inhibition and 1q amp; Larry Boise
  • Resistance to protein degraders; Constantine Mitsiades
  • MRD, Master study and therapy cessation; Luciano Costa
  • Biology of residual clones; Bruno Paiva
  • antiCD38 combinations; Peter Voorhees
  • Nuclear exportin inhibitors; Nizar Bahlis

 

11.40-12.25 Panel Discussion: The development and integration of novel targets

Panel Chairs: Keith Stewart, Jonathon Kaufman, Larry Boise, Peter Voorhees, Meletios Dimopoulos, Shaji Kumar, Luciano Costa, Mohamad Mohty

Discussion points:

  • Sequencing drugs
  • Evaluating drugs in 2021
  • Key targets beyond TCE

 

12.25-13:45 Session 6: T-Cell Engagement Strategies in 2021; current data  | Chair: Ed Staudmauer

  • Overview lecture: T-Cell Engagement Strategies for MM in 2021; current data. Ed Staudtmauer
  • BCMA CAR-T (BMS); Yi Lin
  • BCMA CAR-T (J and J); Deepu Madduri
  • GPRC5D; Niels van den Donk
  • FCRHL5; Adam Cohen
  • AMG 420 BiTE molecule; Max Topp
  • Managing side effects and integration with existing approaches; Nina Shah

 

13.45-14.30 Panel Discussion: T-Cell Engagement Strategies in 2021

Panel Chairs: Ed Staudtmauer, Yi Lin Deepu Madduri, Niels van den Donk, Adam Cohen, Nina Shah.

 

14:30 EST Summary and close of iwMyeloma 2021 | Chairs: Gareth Morgan & Ken Anderson

 

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter